Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Tarceva (erlotinib) survival difference of two weeks to one month, depending on the analysis, is statistically persuasive, FDA’s Oncologic Drugs Advisory Committee says at Sept. 13 meeting.
Advertisement

Related Content

From Avastin To Zevalin: ODAC’s Most Memorable Moments
FDA Approves Tarceva For Pancreatic Cancer
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
FDA Approves Tarceva For Pancreatic Cancer
Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel